Table 1.
Influence of isoprenaline and exercise training on LV morphology and function
| Experimental group |
|||||
|---|---|---|---|---|---|
| Variable | Con (n= 10) | Iso (n= 13) | Ex (n= 8) | Iso+Ex (n= 8) | P value |
| Body weight (g) | 367 ± 13 | 359 ± 7 | 347 ± 21 | 349 ± 16 | 0.70 |
| CSA (mm2) | 0.77 ± 0.04 | 1.30 ± 0.02* | 0.67 ± 0.02 | 0.65 ± 0.02 | <0.001 |
| Echocardiography | |||||
| LVPWd (mm) | 1.44 ± 0.10 | 1.92 ± 0.13* | 1.46 ± 0.06 | 1.54 ± 0.09 | <0.05 |
| LVPWs (mm) | 2.50 ± 0.12 | 3.34 ± 0.15* | 2.46 ± 0.11 | 2.56 ± 0.07 | <0.001 |
| LVEDD (mm) | 7.66 ± 0.21 | 7.11 ± 0.17 | 7.66 ± 0.34 | 7.97 ± 0.18 | 0.06 |
| LVESD (mm) | 4.52 ± 0.16 | 3.12 ± 0.20* | 4.63 ± 0.32 | 5.03 ± 0.15 | <0.001 |
| FS (%) | 41 ± 1 | 56 ± 2* | 40 ± 2 | 37 ± 1 | <0.001 |
| Haemodynamics | |||||
| HR (beats min−1) | 401 ± 9 | 483 ± 20* | 415 ± 10 | 386 ± 15 | <0.01 |
| LVSP (mmHg) | 127 ± 2 | 116 ± 2* | 124 ± 3 | 131 ± 3 | <0.05 |
| LVEDP (mmHg) | 7.9 ± 0.5 | 15.2 ± 0.9* | 6.8 ± 0.8 | 7.3 ± 0.9 | <0.001 |
| +dP/dt (mmHg s−1) | 8023 ± 175 | 10090 ± 354* | 8122 ± 163 | 8313 ± 129 | <0.001 |
| −dP/dt (mmHg s−1) | 6342 ± 296 | 6946 ± 331 | 6569 ± 215 | 6516 ± 156 | 0.43 |
| MAP (mmHg) | 101 ± 3 | 84 ± 3* | 103 ± 3 | 106 ± 3 | <0.01 |
Abbreviations: CSA, cross-section area of papillary muscles; LVPWd, diastolic LV posterior wall thickness; LVPWs, systolic LV posterior wall thickness; LVEDD, LV end-diastolic dimension; LVESD, LV end-systolic dimension; FS, LV fractional shortening; HR, heart rate; LVSP, LV systolic pressure; LVEDP, LV end-diastolic pressure; +dP/dt, maximal positive time derivative of developed pressure; −dP/dt, maximal negative derivative of developed pressure; and MAP, mean arterial pressure.
*
Significant differences by ANOVA vs. other groups.